Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MRKR - US57055L2060 - Common Stock

1.76 USD
-0.06 (-3.3%)
Last: 1/15/2026, 4:04:08 PM
Fundamental Rating

3

MRKR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. MRKR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRKR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year MRKR has reported negative net income.
  • In the past year MRKR has reported a negative cash flow from operations.
  • In the past 5 years MRKR always reported negative net income.
  • In the past 5 years MRKR always reported negative operating cash flow.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • MRKR has a Return On Assets of -65.78%. This is in the lower half of the industry: MRKR underperforms 61.17% of its industry peers.
  • MRKR has a Return On Equity (-77.75%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.78%
ROE -77.75%
ROIC N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MRKR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for MRKR has been increased compared to 1 year ago.
  • MRKR has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • MRKR has an Altman-Z score of -24.98. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -24.98, MRKR is doing worse than 85.04% of the companies in the same industry.
  • MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.98
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 6.50 indicates that MRKR has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.50, MRKR is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • A Quick Ratio of 6.50 indicates that MRKR has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 6.50, MRKR is doing good in the industry, outperforming 67.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.5
Quick Ratio 6.5
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

  • The earnings per share for MRKR have decreased strongly by -12.74% in the last year.
  • The Revenue for MRKR has decreased by -12.99% in the past year. This is quite bad
  • The Revenue has been growing by 99.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-12.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
Revenue 1Y (TTM)-12.99%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-35.98%

3.2 Future

  • MRKR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.25% yearly.
  • MRKR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 81.00% yearly.
EPS Next Y19.82%
EPS Next 2Y-10.63%
EPS Next 3Y5.96%
EPS Next 5Y20.25%
Revenue Next Year-62.78%
Revenue Next 2Y-43.09%
Revenue Next 3Y32.8%
Revenue Next 5Y81%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • MRKR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MRKR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.63%
EPS Next 3Y5.96%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for MRKR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MARKER THERAPEUTICS INC

NASDAQ:MRKR (1/15/2026, 4:04:08 PM)

1.76

-0.06 (-3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners20.7%
Inst Owner Change0%
Ins Owners1.64%
Ins Owner Change0%
Market Cap29.34M
Revenue(TTM)4.70M
Net Income(TTM)-14.30M
Analysts82.22
Price Target8.8 (400%)
Short Float %2.13%
Short Ratio1.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.26%
Min EPS beat(2)30.66%
Max EPS beat(2)73.86%
EPS beat(4)3
Avg EPS beat(4)11.24%
Min EPS beat(4)-87.59%
Max EPS beat(4)73.86%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)41.97%
Min Revenue beat(2)16.75%
Max Revenue beat(2)67.2%
Revenue beat(4)2
Avg Revenue beat(4)1.95%
Min Revenue beat(4)-44.56%
Max Revenue beat(4)67.2%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.61%
PT rev (3m)5.61%
EPS NQ rev (1m)-0.86%
EPS NQ rev (3m)74.95%
EPS NY rev (1m)-0.35%
EPS NY rev (3m)48.73%
Revenue NQ rev (1m)-5.67%
Revenue NQ rev (3m)-5.67%
Revenue NY rev (1m)-1.53%
Revenue NY rev (3m)16.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.25
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.28
BVpS1.1
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.78%
ROE -77.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.5
Quick Ratio 6.5
Altman-Z -24.98
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
EPS Next Y19.82%
EPS Next 2Y-10.63%
EPS Next 3Y5.96%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-12.99%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-35.98%
Revenue Next Year-62.78%
Revenue Next 2Y-43.09%
Revenue Next 3Y32.8%
Revenue Next 5Y81%
EBIT growth 1Y-41.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3430.06%
EBIT Next 3Y-239.79%
EBIT Next 5Y137.29%
FCF growth 1Y27.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.27%
OCF growth 3YN/A
OCF growth 5YN/A

MARKER THERAPEUTICS INC / MRKR FAQ

What is the fundamental rating for MRKR stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRKR.


Can you provide the valuation status for MARKER THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MARKER THERAPEUTICS INC (MRKR). This can be considered as Overvalued.


How profitable is MARKER THERAPEUTICS INC (MRKR) stock?

MARKER THERAPEUTICS INC (MRKR) has a profitability rating of 0 / 10.


Can you provide the financial health for MRKR stock?

The financial health rating of MARKER THERAPEUTICS INC (MRKR) is 6 / 10.